No profile data available.
Elicio Therapeutics, Inc. (ELTX) is a healthcare company in the additional cancer treatment drugs industry, based in Boston, United States, with about 33 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$39.57 million. Its market capitalization was $49.67 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Elicio Therapeutics reported $0 in revenue for fiscal year 2025.
$49.67 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Oncolytics Biotech Inc. (ONCY), Xilio Therapeutics, Inc. (XLO), Boundless Bio, Inc. (BOLD), Werewolf Therapeutics, Inc. (HOWL).